Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment.
Boix
E
E
López
P
P
Pérez-Mateo
M
M
Picó
A
A
D000208:Acute Disease; D000236:Adenoma / Q000188:drug therapy; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006728:Hormones / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D010195:Pancreatitis / Q000139:chemically induced* / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000008:administration & dosage* / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy; D013004:Somatostatin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006728:Hormones; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin
Lancet. 1991 Jul 6;338(8758):52-3
1676101
South Med J. 1991 Nov;84(11):1410-1
1948240
JOP. 2003 Jan;4(1):41-8
12555015
J Clin Endocrinol Metab. 2002 Jan;87(1):99-104
11788630
JOP. 2003 Jan;4(1):33-40
12555014
J Clin Endocrinol Metab. 1997 Jul;82(7):2376-7
9215324
J Clin Endocrinol Metab. 1996 Dec;81(12 ):4502-3
8954072